At the Global Journal of Oncology Drug Development and Care (GJODDC), we are committed to providing timely and impactful scholarly content that drives innovation and excellence in oncology pharmacy practice and cancer therapeutics. Browse our current issue and explore our archived volumes for access to high-quality research and clinical advancements.
Featured Articles in the Latest Issue
- Volume 1 (Issue 2) JULY– DECEMBER 2025
Research Articles
Pharmacokinetic Evaluation and Dose Optimization of a Novel Oral Tyrosine Kinase Inhibitor in Advanced Non-Small Cell Lung Cancer
Vol.1(2); Pages:1-10. Published on July-2025
Abstract
The therapy of advanced non-small cell lung cancer (NSCLC) is still evolving, and novel tyrosine kinase inhibitors (TKIs) have been created. The goal of this Phase I dose-escalation Study was to evaluate the pharmacokinetic (PK) profile, safety and early efficacy of an investigational oral TKI in patients with EGFRpositive NSCLC (n = 24). Three cohorts were used in the study with each one getting an increased dose in a 28- day cycle. PK analysis was done by collecting blood at specific predetermined time points and analyzed by LCMS/MS. The results showed a linear pharmacokinetics and a half-life of 18 hours and no dose-limiting toxicities were observed in the range of therapeutic doses. The incidence of adverse events was highest (Grade 12 nausea and rash). Early tumor response was partial response in 3 patients and stable disease in 11. These results indicate a possibility of further exploration of this TKI at Phase II trials to help in the optimization of dose administration strategies as a means of enhancing therapeutic response in advanced NSCLC.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Novel Liposomal form of Topotecan in Relapsed small Cell Lung cancer: A phase I dose-escalation Study
Vol.1(2); Pages:11-19. Published on July-2025
Abstract
Recurrence of small cell lung cancer (SCLC) following conventional chemotherapy is usually high and few therapeutic alternatives exist. In this dose-escalation Phase I study, the researchers were testing a new nanoliposomal formulation of topotecan, which has greater selectivity in delivering topotecan to tumors with a reduced body burden of toxicity. Twenty-six relapsed SCLC patients were recruited and the maximum tolerated dose (MTD) was determined to be 1.8 mg/m 2. On pharmacokinetic analysis, half-life was prolonged in the plasma and was elevated in the tumour sites as compared to traditional topotecan preparations. Neutropenia appeared to be a dose-limiting toxicity and initial signals of activity included partial responses in 27% and stable disease in 38% of patients. There was also decreased gastrointestinal toxicity as stated by the patients than the standard treatment. These findings validate future Phase II studies and propose that liposomal topotecan has potential to provide useful choice of treatment options in relapsed SCLC.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Assessment of Patient-Reported: Outcomes in Targeted Therapy in Chronic Myeloid Leukemia: A Prospective Observational Study
Vol.1(2); Pages:20-28. Published on July-2025
Abstract
With the introduction of tyrosine kinase inhibitors (TKI)-targeted therapy, chronic myeloid leukemia (CML) treatment became a reality revolution, yet long-term persistence and quality of life (QoL) remain the critical elements toward treatment success. This prospective observational follow-up study used 18 months of followup to assess patient-reported outcomes (PROs) in 210 patients in five European cancer centers on TKI therapy. Fatigue, emotional well-being, burden of treatment and adherence patterns were evaluated using validated questionnaires. The findings showed that 62 percent of patients had severe fatigue and 48 percent claimed to have moderate-intensive burden of treatment. This had to do with every day functions. Nevertheless, compliance was also high (>85%). Multivariate analysis showed that the psychologically oriented support and nurse-led counseling had a positive effect on adherence and QoL. The significance of incorporating the measures of PRO in clinical practice is stressed in this research, and it should be noted that the patient-focused outcomes should be used in treatment planning in management of CML.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Multi-center Phase II study of VEGF Inhibited based Combination Therapy with radiotherapy in Adult Samples with Glioblastoma
Vol.1(2); Pages:29-38. Published on August-2025
Abstract
Glioblastoma (GBM) continues to be an aggressive primary brain tumor with a dismal survival, despite multimodal treatment. In a multicenter phase II study, the role of the combination of VEGF inhibitor (bevacizumab) and standard radiotherapy was examined in 78 patients with newly diagnosed glioblastoma with respect to efficacy. Patients were randomized to take radiotherapy or radiotherapy and bevacizumab. The combination regimen had a meaningful increase in the median progression-free survival (PFS) (11.3 months vs. 7.6 months, p<0.05), but overall survival (OS) benefits were not significant in interim analysis. Peritumoral radiographic edema imagery was low in the combination group, and this led to less corticosteroid usage. Nonsynonymous events such as hypertension and proteinuria, which were aligned to VEGF inhibition but which could be managed by supportive treatment, were also recorded. These findings indicate that the addition of VEGF inhibition to radiotherapy may enhance control of disease progression in glioblastoma, and that the overall survival outcome requires Phase III studies.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Systematic Evaluation and Network-Based Meta-Analysis of Oral SERDs for End-Stage HR-Positive Breast Cancer
Vol.1(2); Pages:39-49. Published on August-2025
Abstract
Selective estrogen receptor degrade (SERDs) are currently observed as candidates of ideal treatment of hormone receptor-positive (HR+) advanced breasts cancer, particularly in patients that do not respond to aromatase inhibitors. The present prospective is a systematic review with network meta-analysis, including 12 randomized controlled clinical trials with 3,142 patients, prescribed oral SERDs, among which there were elacestrant and camizestrant. The comparison was based on the efficacy and tolerability of the analyzed drugs with reference to progression-free survival (PFS) and overall response rate (ORR). The elacestrant was better at PFS over the camizestrant and standard endocrine therapy with the hazard ratios trended in favor of treatment in ESR1-mutant populations. The gastrointestinal and hepatic adverse events were deemed manageable according to safety profiles of all the agents. The analysis of the network gives a comparative analysis of clinical decision-making and shows elacestrant as a future oral SERD option that could be used as a first-line treatment. The results indicate the necessity of a precision-guided application of SERDs and the required long-term outcome trials.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
